Want to see IN:GUJTHEM full AI Analyst Report?
GUJTHEM Stock Chart & Stats
₹432.00
--
Market closed
₹432.00
--
Day’s Range― - ―
52-Week Range₹225.75 - ₹479.45
Previous CloseN/A
VolumeN/A
Average Volume (3M)18.97K
Market Cap
₹42.59B
Enterprise Value₹26.34B
Total Cash (Recent Filing)₹103.83M
Total Debt (Recent Filing)₹714.92M
Price to Earnings (P/E)72.5
Beta2.00
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.2%
Share Statistics
EPS (TTM)2.41
Shares Outstanding130,151,700
10 Day Avg. Volume18,082
30 Day Avg. Volume18,968
Financial Highlights & Ratios
PEG Ratio-11.90
Price to Book (P/B)8.62
Price to Sales (P/S)14.96
P/FCF Ratio-19.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.9
Revenue Forecast (FY)₹1.88B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth of about 107% materially expands the company’s operating scale and indicates strong demand across its pharmaceutical activities. If this momentum persists, higher volume can support earnings capacity, strengthen market presence, and provide resources for continued business development.
ProfitabilityHigh EBIT and net margins demonstrate that the company has retained substantial profitability despite its rapid expansion. This provides an important earnings buffer, supports internal funding capacity, and indicates that the business can convert a meaningful portion of revenue into profit.
Pharmaceutical Business BaseParticipation across pharmaceutical formulations and APIs, combined with domestic and export markets, gives Gujarat Themis Biosyn a broad operating base. Contract manufacturing and B2B supply arrangements where applicable can further diversify routes to market and support durable customer demand.
Bears Say
Weak Cash GenerationCash generation has weakened substantially even as reported revenue expanded. Lower operating cash flow and sharply negative free cash flow mean profits are providing less liquidity, while ongoing investment or working-capital needs could increase reliance on external funding if this pattern persists.
Higher LeverageThe rapid increase in debt relative to equity reduces financial flexibility and raises the company’s exposure to weaker margins or demand. Higher leverage can constrain future capital allocation and make it more difficult to absorb operating volatility without relying on additional financing.
Margin CompressionThe sharp gross-margin decline shows that revenue growth is not translating proportionately into earnings quality. A slight net-income decrease despite much higher sales suggests cost, mix, or non-operating pressure, creating a durable risk to the sustainability of recent profitability.
Gujarat Themis Biosyn Ltd News
GUJTHEM FAQ
What was Gujarat Themis Biosyn Ltd’s price range in the past 12 months?
Gujarat Themis Biosyn Ltd lowest stock price was ₹225.75 and its highest was ₹479.45 in the past 12 months.
What is Gujarat Themis Biosyn Ltd’s market cap?
Gujarat Themis Biosyn Ltd’s market cap is ₹42.59B.
When is Gujarat Themis Biosyn Ltd’s upcoming earnings report date?
Gujarat Themis Biosyn Ltd’s upcoming earnings report date is Nov 14, 2026 which is in 21 days.
How were Gujarat Themis Biosyn Ltd’s earnings last quarter?
Gujarat Themis Biosyn Ltd released its earnings results on Aug 07, 2026. The company reported ₹1.016 earnings per share for the quarter.
Is Gujarat Themis Biosyn Ltd overvalued?
According to Wall Street analysts Gujarat Themis Biosyn Ltd’s price is currently Overvalued.
Does Gujarat Themis Biosyn Ltd pay dividends?
Gujarat Themis Biosyn Ltd pays a Annually dividend of ₹0.67 which represents an annual dividend yield of 0.2%. See more information on Gujarat Themis Biosyn Ltd dividends here
What is Gujarat Themis Biosyn Ltd’s EPS estimate?
Gujarat Themis Biosyn Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gujarat Themis Biosyn Ltd have?
Gujarat Themis Biosyn Ltd has 130,151,700 shares outstanding.
What happened to Gujarat Themis Biosyn Ltd’s price movement after its last earnings report?
Gujarat Themis Biosyn Ltd reported an EPS of ₹1.016 in its last earnings report. Following the earnings report the stock price went down -1.233%.
Which hedge fund is a major shareholder of Gujarat Themis Biosyn Ltd?
Currently, no hedge funds are holding shares in IN:GUJTHEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Ltd. is an Indian company primarily involved in the creation of pharmaceuticals and medicinal chemicals. The firm also supplies bulk drugs via a job work model within India. Its product offerings include important compounds such as Rifamycin-S, an intermediate used in treatments for tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease. Another key product, Rifamycin-O, addresses ailments like traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy. Furthermore, they produce Lovastatin. Established in 1981, the company's operations are based out of Mumbai, India.
Technical Analysis
Gufic Biosciences Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Morepen Laboratories Limited
―
Orchid Pharma Limited
―
Unichem Laboratories Limited
―